GLIDR: A Promising Drug Target and Biomarker (G389741)

Target Name: GLIDR

NCBI ID: G389741

GLIDR

GLIDR: A Promising Drug Target and Biomarker

GLIDR (LINC01172) is a drug target and potential biomarker that has been identified for its role in the treatment of various diseases, including cancer. GLIDR is a gene that has been shown to play a crucial role in the development and progression of various diseases, including cancer.

Studies have shown that GLIDR is involved in the regulation of cell growth, apoptosis (programmed cell death), and angiogenesis (the formation of new blood vessels). GLIDR has also been shown to be involved in the regulation of cellular processes that are important for cancer progression, such as the regulation of the immune response and the regulation of the blood supply.

One of the key benefits of GLIDR as a drug target is its potential to treat a wide range of diseases, including cancer. Cancer is a leading cause of death worldwide, and there is a significant need for new and effective treatments. GLIDR has been shown to have potential as a cancer treatment by inhibiting its activity and triggering apoptosis in cancer cells.

GLIDR has also been shown to have potential as a biomarker for cancer. By detecting the expression of GLIDR in cancer cells, researchers can monitor the effectiveness of new treatments and track disease progression. This has the potential to improve the accuracy and effectiveness of cancer treatments.

In addition to its potential as a cancer treatment and biomarker, GLIDR has also been shown to have potential as an underlying cause of various diseases. For example, GLIDR has been shown to be involved in the development and progression of neurodegenerative diseases, such as Alzheimer's and Parkinson's.

Overall, GLIDR is a promising drug target and biomarker that has the potential to revolutionize the treatment of various diseases, including cancer. Further research is needed to fully understand its role and potential as a drug and biomarker.

Protein Name: Glioblastoma Down-regulated RNA

The "GLIDR Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GLIDR comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets